


Patent Claims**1. Use of the compounds of the formula I**

5



10

in which

X denotes CH or N,

15

R¹ denotes H, A, Hal, (CH₂)_nHet, (CH₂)_nAr, cycloalkyl having 3 to 7 C atoms, CF₃, NO₂, CN, C(NH)NOH or OCF₃,

15

R² denotes (CH₂)_nHet, (CH₂)_nAr, cycloalkyl having 3 to 7 C atoms or CF₃,

20

R³, R⁴ denote H, (CH₂)_nCO₂R⁵, (CH₂)_nCOHet, (CH₂)_nCON(R⁵)₂, (CH₂)_nCOO(CH₂)_nHet, CHO, (CH₂)_nOR⁵, (CH₂)_nHet, (CH₂)_nN(R⁵)₂, CH=N-OA, CH₂CH=N-OA, (CH₂)_nNHOA, (CH₂)_nN(R⁵)Het, (CH₂)_nCH=N-Het, (CH₂)_nOCOR⁵, (CH₂)_nN(R⁵)CH₂CH₂OR⁵, (CH₂)_nN(R⁵)CH₂CH₂OCF₃,

25

(CH₂)_nN(R⁵)C(R⁵)HCOOR⁵, (CH₂)_nN(R⁵)CH₂COHet, (CH₂)_nN(R⁵)CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂N(R⁵)CH₂COOR⁵,

30

(CH₂)_nN(R⁵)CH₂CH₂OR⁵, (CH₂)_nN(R⁵)CH₂CH₂N(R⁵)₂, CH=CHCOOR⁵, CH=CHCH₂NR⁵Het, CH=CHCH₂N(R⁵)₂, CH=CHCH₂OR⁵, CH=CHCH₂Het, (CH₂)_nN(R⁵)Ar, (CH₂)_nN(COOR⁵)COOR⁵, (CH₂)_nN(CONH₂)COOR⁵, (CH₂)_nN(CONH₂)CONH₂, (CH₂)_nN(CH₂COOR⁵)COOR⁵, (CH₂)_nN(CH₂CONH₂)COOR⁵, (CH₂)_nN(CH₂CONH₂)CONH₂, (CH₂)_nCHR⁵COR⁵, (CH₂)_nCHR⁵COOR⁵, (CH₂)_nCHR⁵CH₂OR⁵, where in each case one of the radicals R³ or R⁴ has the meaning H,

35

R⁵ denotes H or A

5 A denotes straight-chain or branched alkyl or cycloalkyl having 2 to 4 C atoms, having 1 to 10 C atoms, alkenyl having 2 to 10 C atoms, alkoxyalkyl having 2 to 10 C atoms or cycloalkyl having 4 to 7 C atoms, each of which is unsubstituted or substituted by Hal or CN,

10 Het preferably denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical having 1 to 15 C atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal or a linear radical having 1 to 15 C atoms containing one or two hetero atoms,

15 Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, OR⁵, OOCR⁵, COOR⁵, CON(R⁵)₂, CN, NO₂, NH₂, NHCOR⁵, CF₃ or SO₂CH₃,

20 n denotes 0, 1, 2, 3, 4 or 5

and

Hal denotes F, Cl, Br or I,

25 and salts and solvates, enantiomers and racemates thereof for the preparation of a medicament for the treatment and prophylaxis of diseases which can be influenced by the binding of the compounds of the formula I to 5 HT receptors.

30 2. Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT receptor-antagonistic action.

35 3. Use of compounds according to Claim 1 or 2 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT_{2A} receptor-antagonistic action.

4. Use of compounds of the formula I according to Claim 1, 2 or 3 and/or physiologically acceptable salts or solvates thereof for the preparation of a medicament for the prophylaxis and/or treatment of psychoses, neurological disorders, amyotrophic lateral sclerosis, eating disorders, such as bulimia, anorexia nervosa, of premenstrual syndrome and/or for positively influencing obsessive-compulsive disorder (OCD).
5. Use of the compounds of the formula I according to one or more of the preceding claims, in which R¹ denotes phenyl, 2-, 3- or 4-cyano-phenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, di-chloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl.
10. Use of the compounds of the formula I according to one or more of the preceding claims, in which R³ denotes (CH₂)_nCO₂R⁵, (CH₂)_nCO-Het, CHO, CH₂OR⁵, (CH₂)_n-Het, (CH₂)_nN(R⁵)₂ or CH=N-OA, (CH₂)_nN(R⁵)Het, (CH₂)_nN(R⁵)CH₂CH₂OR⁵, (CH₂)_nN(R⁵)CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂N(R⁵)₂, CH=CHCH₂NR⁵Het, CH=CHCH₂N(R⁵)₂, CH=CHCH₂OR⁵, CH=CHCH₂Het or (CH₂)_nN(R⁵)Ar.
15. Use of the compounds of the formula I according to one or more of the preceding claims, in which R⁴ denotes H.
20. Use of the compounds of the formula I according to one or more of the preceding claims, in which R² denotes phenyl, 2-, 3- or 4-cyano-phenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl.
25. Use of the compounds of the formula I according to one or more of the preceding claims, in which X has the meaning CH.
30. Use of the compounds of the formula I according to one or more of the preceding claims, in which X has the meaning CH.
35. Use of the compounds of the formula I according to one or more of the preceding claims, in which X has the meaning CH.

10. Use of the compounds of the formula (a) to (o) according to Claim 1:
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-ylmethyl]- (a)
(4-methylpiperazin-1-yl)amine

5 4-{2-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl]- (b)
ethyl}morpholine

10 4-{3-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4- (c)
yl]allyl}morpholine

15 1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl- (d)
methyl]pyrrolidin-3-ol

20 1-[1-(4'-fluorobiphenyl-4-yl)-5-(2-fluorophenyl)-1H-pyrazol- (e)
4-ylmethyl]-4-methylpiperazine

25 1-[5-(2-fluorophenyl)-1-(4-thiophen-3-ylphenyl)-1H-pyrazol-4-yl- (f)
methyl]-4-methylpiperazine

30 N¹-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl- (g)
methyl]ethane-1,2-diamine

35 2-{[1-biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl- (i)
methyl]amino}ethanol

 [1-biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-ylmethyl]- (j)
(2-methoxyethyl)amine

 2-{[1-biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl- (k)
methyl]methylamino}ethanol

 1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl- (l)
methyl]-4-methyl-[1,4]diazepam

 1-[1-(4'-fluorobiphenyl-4-yl)-5-phenyl-1H-pyrazol-4-yl- (m)
methyl]-4-methylpiperazine

 1-[5-(2-fluorophenyl)-1-(4-pyrrol-1-ylphenyl)-1H-pyrazol-4- (n)
ylmethyl]-4-methylpiperazine

 [1-biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-ylmethyl]- (o)
methyl-(1-methylpyrrolidin-3-yl)amine

and salts and solvates thereof.